Rassanee Bissanum

ORCID: 0000-0003-0526-813X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Extracellular vesicles in disease
  • Cancer-related molecular mechanisms research
  • Breast Cancer Treatment Studies
  • Cancer Cells and Metastasis
  • Renal cell carcinoma treatment
  • Cancer Genomics and Diagnostics
  • FOXO transcription factor regulation
  • Ferroptosis and cancer prognosis
  • Circular RNAs in diseases
  • Cancer Mechanisms and Therapy
  • AI in cancer detection
  • Renal and related cancers
  • Sesquiterpenes and Asteraceae Studies
  • Metabolism, Diabetes, and Cancer
  • Air Quality and Health Impacts
  • Natural product bioactivities and synthesis
  • Inflammatory Biomarkers in Disease Prognosis
  • Bioactive Compounds and Antitumor Agents

Prince of Songkla University
2017-2023

Institute of Biomedical Science
2022

Breast cancer is the leading cause of female mortality worldwide. Although there are several modern treatments for breast cancer, a high rate recurrence majority treatments; therefore, search effective anticancer agents continues. The present study aimed to investigate anti-breast potential frullanolide, compound which isolated and purified from Grangea maderaspatana plant, selected human cell lines (MCF-7, MDA-MB-468 MDA-MB-231). MTT assay was used assess cytotoxic activity in treatment...

10.3892/ol.2019.10209 article EN Oncology Letters 2019-04-03

Triple-negative breast cancer (TNBC) presents an important clinical challenge, as it does not respond to endocrine therapies or other available targeting agents. FOXM1, oncogenic transcriptional factor, has reported be upregulated and associated with poor outcomes in TNBC patients. In this study, we investigated the anti-cancer effects of FDI-6, a FOXM1 inhibitor, well its molecular mechanisms, cells. Two cell lines, MDA-MB-231 HS578T, were used study. The activities FDI-6 evaluated using...

10.3390/ijms22136685 article EN International Journal of Molecular Sciences 2021-06-22

Triple negative breast cancer (TNBC) lacks well-defined molecular targets and is highly heterogenous, making treatment challenging. Using gene expression analysis, TNBC has been classified into four different subtypes: basal-like immune-activated (BLIA), immune-suppressed (BLIS), mesenchymal (MES), luminal androgen receptor (LAR). However, there currently no standardized method for classifying subtypes. We attempted to define a signature each subtype, develop classification based on machine...

10.3390/jpm11090881 article EN Journal of Personalized Medicine 2021-09-01

Triple-negative breast cancer (TNBC) is a heterogeneous disease associated with late-stage diagnosis and high metastatic rates. However, gene signature for reliable TNBC biomarkers not available yet. We aimed to identify potential key genes their association poor prognosis in through integrated bioinformatics.Microarray datasets were downloaded from the Gene Expression Omnibus (GEO) database. Differentially expressed (DEGs) vs. non-TNBC normal tissues analyzed. Overlapping upregulated...

10.21037/tcr-22-662 article EN Translational Cancer Research 2022-08-23

Urinary extracellular vesicles (uEVs) reflect the biological conditions of producing cells. The protein profiling uEVs allow us to better understand cancer progression in several cancers such as bladder cancer, prostate and kidney but has not been reported breast cancer. We have, herein, aimed at quantifying concentration generating proteomic profile patients with (BC) compared that healthy controls (CT). Urine samples were collected from 29 CT 47 BC. isolated by using differential...

10.1371/journal.pone.0291574 article EN cc-by PLoS ONE 2023-11-03

Cervical cancer (CC) is the fourth most common type and a leading cause of cancer-related deaths in women worldwide. Its underlying molecular mechanisms are unclear. Cancer cell-derived extracellular vesicles (EVs) involved development progression by delivering regulatory factors, including microRNAs long non-coding RNAs (lncRNAs).

10.1159/000533145 article EN Oncology 2023-08-12
Coming Soon ...